GH Research reports Q3 2025 results with $293.9 million cash and durable 5-MeO-DMT data

GH Research PLC (GHRS) — GH Research reported third-quarter 2025 results, ending the period with $293.9 million in cash and marketable securities.

The company highlighted its Phase 2b program for inhalable 5-MeO-DMT (GH001) in treatment-resistant depression, including an open-label extension showing a 73% remission rate at six months, and reaffirmed plans to start a global pivotal program in 2026. It also continued working with the FDA to resolve the remaining topic on its U.S. IND clinical hold.

Source: globenewswire.com

For the rest of that week's sector news, read our week in review.